- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00624156
Expressive Writing and Adjustment to Metastatic Breast Cancer
October 28, 2015 updated by: Memorial Sloan Kettering Cancer Center
We are doing this study to see if writing about life experiences helps women adjust to breast cancer that has spread.
We will compare two groups.
One group will write about their breast cancer experience.
The other will write about their daily activities.
What we learn from this study may help us to find new ways to help women cope with breast cancer that has spread.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
98
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
MSKCC clinics
Description
Inclusion Criteria:
- Women with Stage IV breast cancer
- Receiving cancer care at Memorial Sloan-Kettering Cancer Center
- At least 18 years of age
- Can speak, read, and write in English
- In the judgment of consenting professionals able to provide informed consent
- Score of 4 or higher on the distress thermometer (established cutoff score for probable distress; see Jacobsen et al., 2005)
Exclusion Criteria:
- Significant psychiatric or cognitive impairment (dementia/delirium, retardation, psychosis) that in the judgment of the investigators will preclude providing informed consent and participating in the intervention
- Currently engaging in expressive writing (e.g., journal writing that involves expressing one's feelings) on a daily basis
- Currently participating in intervention trials with similar endpoints • Male
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
emotional disclosure writing intervention
|
Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
Other Names:
Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities.
The 20-minute writing task will be introduced as a time management intervention
Other Names:
|
2
control writing
|
Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
Other Names:
Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities.
The 20-minute writing task will be introduced as a time management intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the potential utility of expressive writing for enhancing existential well-being (i.e., increasing a sense of meaning and peace and reducing demoralization) among women with metastatic breast cancer.
Time Frame: conclusion of the study
|
conclusion of the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the potential utility of expressive writing for reducing distress (i.e., depressive symptoms, anxiety, cancer-specific and general distress) among women with metastatic breast cancer.
Time Frame: conclusion of the study
|
conclusion of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Katherine DuHamel, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
February 15, 2008
First Submitted That Met QC Criteria
February 25, 2008
First Posted (Estimate)
February 26, 2008
Study Record Updates
Last Update Posted (Estimate)
October 30, 2015
Last Update Submitted That Met QC Criteria
October 28, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
Clinical Trials on Writing Intervention
-
University of WaterlooCompletedThe Effects of Expressive Writing and Compassionate Letter Writing on Emotional Distress IntoleranceDistress IntoleranceCanada
-
University of Roma La SapienzaCompleted
-
University of California, Los AngelesRecruiting
-
University of SaskatchewanSaskatchewan Health Research FoundationCompleted
-
Black Hills State UniversityNational Institute of General Medical Sciences (NIGMS)Not yet recruitingAcute Pain | Emotions | Positive Thinking
-
Arizona State UniversityCancer Support Community ArizonaRecruitingQuality of Life | Distress, EmotionalUnited States
-
Massachusetts Institute of TechnologyNorthwestern University; Columbia University; University of FloridaCompleted
-
Dartmouth-Hitchcock Medical CenterNational Endowment for the Arts, United StatesCompleted
-
University of WaterlooSt. Joseph's Healthcare HamiltonEnrolling by invitationAnorexia Nervosa | Binge-Eating Disorder | Bulimia Nervosa | Compassion | Eating DisordersCanada
-
Yale UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsNot yet recruitingParent-Child RelationsUnited States, Israel